Perspective [CATX] vs Establishment Labs [ESTA] Detailed Stock Comparison

Perspective Therapeutics Inc.

NYSE
Loading...

Establishment Labs Holdings Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Perspective Therapeutics Inc. wins in 8 metrics, Establishment Labs Holdings Inc. wins in 10 metrics, with 0 ties. Establishment Labs Holdings Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Perspective Therapeutics Inc. Establishment Labs Holdings Inc. Better
P/E Ratio (TTM) -3.22 -37.89 Perspective Therapeutics Inc.
Price-to-Book Ratio 1.62 79.68 Perspective Therapeutics Inc.
Debt-to-Equity Ratio 1.57 1,123.15 Perspective Therapeutics Inc.
PEG Ratio -3.84 0.41 Establishment Labs Holdings Inc.
EV/EBITDA -3.38 -70.21 Perspective Therapeutics Inc.
Profit Margin (TTM) 0.00% -24.19% Perspective Therapeutics Inc.
Operating Margin (TTM) -92,632.56% -6.08% Establishment Labs Holdings Inc.
Return on Equity -41.65% -133.25% Perspective Therapeutics Inc.
Return on Assets (TTM) -23.35% -6.93% Establishment Labs Holdings Inc.
Free Cash Flow (TTM) $-95.23M $-57.61M Establishment Labs Holdings Inc.
1-Year Return 53.31% 105.37% Establishment Labs Holdings Inc.
Price-to-Sales Ratio (TTM) 581.70 8.92 Establishment Labs Holdings Inc.
Enterprise Value $372.36M $2.07B Establishment Labs Holdings Inc.
EV/Revenue Ratio 421.22 9.79 Establishment Labs Holdings Inc.
Gross Profit Margin (TTM) N/A 70.46% N/A
Revenue per Share (TTM) $0 $7 Establishment Labs Holdings Inc.
Earnings per Share (Diluted) $-1.41 $-1.72 Perspective Therapeutics Inc.
Beta (Stock Volatility) 1.87 1.08 Establishment Labs Holdings Inc.
Short % of Float 14.32% 22.26% Perspective Therapeutics Inc.

Perspective Therapeutics Inc. vs Establishment Labs Holdings Inc. Stock Performance Analysis

Loading Price Chart...

CATX
ESTA

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Perspective Therapeutics Inc.-1.81%-13.46%-9.55%-32.71%75.61%29.03%
Establishment Labs Holdings Inc.3.00%-3.07%0.24%-7.48%4.34%2.28%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Perspective Therapeutics Inc.53.31%-28.36%-55.73%-54.19%-62.48%-91.24%
Establishment Labs Holdings Inc.105.37%6.40%-6.53%167.87%167.87%167.87%

Performance & Financial Health Analysis: Perspective Therapeutics Inc. vs Establishment Labs Holdings Inc.

MetricCATXESTA
Market Information
Market Cap i$514.22M$1.91B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,385,860451,437
90 Day Avg. Volume i1,439,677478,309
Last Close$3.54$72.52
52 Week Range$1.96 - $6.16$33.35 - $83.31
% from 52W High-42.61%-12.95%
All-Time High$85.00 (Dec 12, 2005)$93.80 (Apr 18, 2022)
% from All-Time High-95.84%-22.69%
Growth Metrics
Quarterly Revenue GrowthN/A0.45%
Quarterly Earnings GrowthN/A0.45%
Financial Health
Profit Margin (TTM) i0.00%-0.24%
Operating Margin (TTM) i-926.33%-0.06%
Return on Equity (TTM) i-0.42%-1.33%
Debt to Equity (MRQ) i1.571,123.15
Cash & Liquidity
Book Value per Share (MRQ)$2.79$0.80
Cash per Share (MRQ)$1.27$2.58
Operating Cash Flow (TTM) i$-82,484,000$-50,890,000
Levered Free Cash Flow (TTM) i$-60,373,500$-41,574,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Perspective Therapeutics Inc. vs Establishment Labs Holdings Inc.

MetricCATX (Apr 26, 2026)ESTA (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-3.22-37.89
Forward P/E i-3.84316.35
PEG Ratio i-3.840.41
Price to Sales (TTM) i581.708.92
Price to Book (MRQ) i1.6279.68
Market Capitalization
Market Capitalization i$514.22M$1.91B
Enterprise Value i$372.36M$2.07B
Enterprise Value Metrics
Enterprise to Revenue i421.229.79
Enterprise to EBITDA i-3.38-70.21
Risk & Other Metrics
Beta i1.871.08
Book Value per Share (MRQ) i$2.79$0.80

Financial Statements Comparison: Perspective Therapeutics Inc. vs Establishment Labs Holdings Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCATX (2025)ESTA (2025)
Revenue/Sales i0211.08M
Cost of Goods Sold iN/A64.77M
COGS % of Revenue i-30.7%
Gross Profit iN/A146.31M
Gross Margin i-69.3%
Research & Development i84.22M20.25M
Operating Income (EBIT) i-113.56M-39.01M
Operating Margin i--18.5%
EBITDA i-100.80M-22.29M
EBITDA Margin i--10.6%
Pre-Tax Income i-104.43M-58.02M
Pre-Tax Income % of Revenue i--27.5%
Income Tax i-793,000-6.96M
Income Tax % of Revenue i--3.3%
Net Income (Profit) i-103.12M-51.06M
Profit Margin i--24.2%

Balance Sheet & Liquidity Metrics

MetricCATX (2025)ESTA (2025)
Cash & Equivalents i30.63M75.57M
Total Current Assets i148.39M249.94M
Total Current Assets % of Revenue i-118.4%
Total Current Liabilities i28.68M82.14M
Total Current Liabilities % of Revenue i-38.9%
Long-Term Debt i2.57M250.34M
Long-Term Debt % of Revenue i-118.6%
Total Shareholders Equity i207.03M23.55M
Retained Earnings i-334.84M-495.76M
Retained Earnings % of Revenue i--234.9%
Property, Plant & Equipment i77.75M4.34M

Cash Flow Statement Comparison

MetricCATX (2025)ESTA (2025)
Operating Cash Flow i-92.65M-50.78M
Operating Cash Flow % of Revenue i--24.1%
Capital Expenditures i-12.75M-6.05M
Free Cash Flow i-95.23M-57.61M
FCF Margin i--27.3%
Debt Repayment i-52,000-1.02M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricCATXESTA
Shares Short i13.67M5.22M
Short Ratio i9.729.90
Short % of Float i14.32%22.26%
Shares Outstanding i74.34M29.30M
Float Shares i74.26M19.22M
% Held by Insiders i10.82%10.16%
% Held by Institutions i54.41%102.08%
% Held by Public i34.77%-12.24%

Dividend Analysis & Yield Comparison: Perspective Therapeutics Inc. vs Establishment Labs Holdings Inc.

MetricCATXESTA
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A